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Abstract
Purpose Visual changes on radionuclide bone scans have
been reported with teriparatide treatment. To assess this,
serial studies were evaluated and quantified in ten post-
menopausal women with osteoporosis treated with teripara-
tide (20 μg/day subcutaneous) who had
99mTc-methylene
diphosphonate (MDP) bone scans (baseline, 3 and
18 months, then after 6 months off therapy).
Methods Women were injected with 600 MBq
99mTc-MDP,
and diagnostic bone scan images were assessed at 3.5 h.
Additional whole-body scans (10 min, 1, 2, 3 and 4 h) were
analysed for
99mTc-MDP skeletal plasma clearance (Kbone).
Regional Kbone differences were obtained for the whole
skeleton and six regions (calvarium, mandible, spine,
pelvis, upper and lower extremities). Bone turnover
markers (BTM) were also measured.
Results Most subjects showed visual changes on 3- and 18-
month bone scan images that disappeared after 6 months off
therapy. Enhanced uptake was seen predominantly in the
calvarium and lower extremities. Whole skeleton Kbone
displayed a median increase of 22% (3 months, p=0.004)
and 34% (18 months, p=0.002) decreasing to 0.7%
(6 months off therapy). Calvarium Kbone changes were three
times larger than other sites. After 6 months off therapy, all
Kbone and BTM values returned towards baseline.
Conclusion The increased
99mTc-MDP skeletal uptake with
teriparatide indicated increased bone formation which was
supported by BTM increases. After 6 months off therapy,
metabolic activity diminished towards baseline. The mod-
ulation of
99mTc-MDP skeletal uptake during treatment was
the result of teriparatide’s metabolic activity. These findings
may aid the radiological evaluation of similar teriparatide
patients having radionuclide bone scans.
Keywords Teriparatide. 99mTc-MDP bone scan.Bone
turnover markers.Bone remodelling.Osteoporosis
Introduction
Radionuclide bone scan imaging using the radiopharma-
ceutical
99mTc-methylene diphosphonate (MDP) has a
useful role in both clinical practice and research to
investigate metabolic bone diseases and response to
treatment [1–3]. In clinical practice, bone scans are reported
solely on a qualitative visual interpretation of images
allowing for the detection of discrete changes in the
skeleton in areas of focal tracer uptake. In the research
setting, methods have been developed to translate visual
assessments into quantitative data [4–7]. Skeletal plasma
clearance of
99mTc-MDP [Kbone (ml/min)] measures the
bone metabolic activity taking into account both the amount
of radionuclide tracer cleared from plasma into bone and
the blood input function. This quantitative measurement
can be used to study the whole skeleton and regions of
interest (ROI) [7].
Osteoporosis is a common skeletal disorder character-
ized by compromised bone strength predisposing a person
to increased risk of fracture [8]. In the USA, 10 million
individuals are estimated to have the disease, with
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fractures annually [9]. Recombinant human parathyroid
hormone fragment rhPTH(1–34) (teriparatide) is an ana-
bolic therapy approved for use in women with postmeno-
pausal osteoporosis, men with primary or hypogonadal
osteoporosis, and patients with osteoporosis associated with
sustained, systemic glucocorticoid therapy, all of whom are
at high risk for fracture [10–12]. Teriparatide preferentially
stimulates osteoblast over osteoclast activity resulting in
new bone formation and an increase in the rate of bone
remodelling. These effects manifest as an increase in
skeletal mass, bone mineral density (BMD) and bone
strength, subsequently leading to a reduction in the risk of
fractures [13–19]. While it has been well established that
teriparatide increases bone remodelling in the skeleton
through histomorphometry studies [18, 20, 21] and meas-
urements of global bone turnover markers (BTM) [13, 17,
19], direct measurements of the effect of teriparatide on the
metabolic activity of the skeleton have not been
performed. Furthermore, questions have been raised by
physicians regarding scintigraphic changes observed in
patients taking teriparatide who have subsequently
undergone radionuclide bone scan studies to evaluate
other potential skeletal conditions [22], including a case
of Paget’s disease of bone [23].
This analysis evaluated the visual changes in the whole-
body
99mTc-MDP bone scan images in ten subjects who had
bone scans at baseline, 3 and 18 months of treatment with
teriparatide, and after 6 months off therapy. We also
measured levels of BTM and the skeletal plasma clearance
of
99mTc-MDP in the whole skeleton and six ROI
(calvarium, mandible, spine, pelvis, and upper and lower
extremities) on treatment and after 6 months withdrawal
from teriparatide.
Materials and methods
Study population
Ten postmenopausal Caucasian women with osteoporosis
were treated with teriparatide 20 μg/day by subcutaneous
self-injection for 18 months followed by 6 months off
therapy. A description of the subjects in this prospective,
exploratory, Phase 4, open-label study was previously
published [24]. Briefly, women were required to be
between 50 and 85 years old and to have a total hip,
femoral neck or lumbar spine BMD T-score≤−2.5 or<−2.0
if they had a history of vertebral or non-vertebral fracture
[25]. Hip and lumbar spine T-scores were calculated using
the Third National Health and Nutrition Examination
Survey (NHANES III) reference range [26]a n dt h e
manufacturer’s reference range (Hologic Inc., Bedford,
MA, USA), respectively. Subjects were excluded from the
trial if they had a bone disorder, other than osteoporosis,
that affected bone metabolism or if they had significant
exposure to bone-active therapies prior to enrolment. For
2 months prior to the baseline visit and until the 24-month
visit, study participants received daily supplements of
calcium (1,000 mg) and vitamin D (400–1,200 IU). The
trial was conducted in accordance with good clinical
practices and the Declaration of Helsinki. The local Ethics
Committee approved the study and all women gave written
informed consent.
Quantitative measurements of bone metabolism
using
99mTc-MDP
Subjects underwent gamma camera bone scan imaging at
baseline, 3 and 18 months after starting teriparatide
therapy, and 6 months after stopping treatment. A dual-
head gamma camera (ADAC Forte, ADAC Laboratories,
Milpitas, CA, USA) was used to acquire anterior and
posterior whole-body images with a scan speed of 25 cm/
min at 10 min and at 1, 2, 3 and 4 h following intravenous
injection of 600 MBq
99mTc-MDP. For visual assessment of
the bone scan images, a standard diagnostic scan (scan
speed 10 cm/min) was performed at 3.5 h. Subjects were
advised to be well hydrated and, with the exception of the
10-min images, to empty their bladders before each whole-
body scan. Upon completion of the 1-, 2-, 3- and 4-h scans,
5-min right and left lateral spot views of the skull were
acquired.
The method used to quantify the bone scan images
was described previously [24]. After correction for
background, urine activity in the bladder and kidneys,
and radioactive decay, the whole-body retention of
99mTc-
MDP was measured from the geometric mean of anterior
and posterior total body counts by normalizing to the
whole-body count (including bladder and kidneys) at
10 min, which was defined as 100% [7]. Four regional
sites (spine, pelvis, upper and lower extremities) were also
analysed by copying ROIs defined on the 4-h anterior and
posterior images (Fig. 1a) onto the 10-min and 1-, 2- and
3-h whole-body images [7]. The geometric mean of
anterior and posterior counts was normalized to the 10-
min whole-body count to express the results as the
percentage of injected activity.
For the calvarium and mandible, the retention of
99mTc-
MDP was measured by drawing appropriate ROI on the
lateral images of the skull obtained at 4 h (Fig. 1b). These
ROI were copied onto the 1-, 2- and 3-h images, and, after
correction for background counts and radioactive decay, the
geometric mean of the counts in the 1-, 2-, 3- and 4-
h images were normalized to the geometric mean of the
counts from a point source of known activity measured
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absolute uptake [27].
The
99mTc-MDP plasma time-activity curve was mea-
sured by taking blood samples at 5 and 20 min and 1, 2, 3
and 4 h after injection via an indwelling venous cannula in
the opposite arm to the injection site. After blood sample
centrifugation, 2 ml of plasma was placed in 10-kDa filters
(Amicon Ultra-4, Millipore Corp., Bedford, MA, USA) and
spun for 30 min at 2,000 g [28]. An automatic gamma
counter was used to determine the plasma concentration of
free and total
99mTc-MDP in 1-ml aliquots of ultrafiltrate
and whole plasma.
Whole skeleton Kbone and regional values of Kbone for
the calvarium, mandible, spine, pelvis, and upper and
lower extremities were derived using the Patlak plot
method [24]. Figures for percentage
99mTc-MDP uptake
(bone plus soft tissue) in each ROI divided by the plasma
concentration (% ml
−1) of total (free plus bound)
99mTc-
MDP were plotted on the vertical axis, and figures for the
area under the plasma clearance curve (AUC) for free
99mTc-MDP divided by the total
99mTc-MDP plasma
concentration were plotted on the horizontal axis. Kbone
(ml min
−1) was derived from the slope of the straight line
fitted to the 2-, 3- and 4-h data points [7].
Qualitative visual scoring of the
99mTc-MDP bone scan
images
Qualitative visual scoring of changes in the diagnostic bone
scan images at all four visits was performed by three
reviewers who jointly classified the changes in whole
skeleton or a regional site into the following groups as
compared to baseline: (1) possible decreased uptake, (2) no
discernible change in uptake, (3) possible increased uptake
and (4) definite increased uptake.
BMD measurements and biochemical markers of bone
turnover
BMD in the lumbar spine (L1–L4) and left hip was
measured at baseline and 18 months using dual-energy X-
ray absorptiometry (DXA) (Hologic Inc., Bedford, MA,
USA). The long-term precision was 1.6% for both spine
and total hip BMD [29].
Fasting concentrations of BTM were measured at
baseline and 3, 12, 18 and 24 months. The bone formation
markers were serum procollagen type I N-terminal propep-
tide [PINP, Orion Diagnostica, Espoo, Finland; interassay
coefficient of variance (CV) 3.1–8.2%] and serum bone-
specific alkaline phosphatase (BSAP, Hybritech, Beckman
Coulter, Brea, CA, USA; interassay CV 7.4–7.9%). The
bone resorption marker was urinary excretion of N-terminal
telopeptide (NTX, Ostex, Seattle, WA USA; interassay CV
6.7–14.8%) normalized to creatinine. The reference ranges
for the BTM in postmenopausal women were specified by
the central laboratory (Covance CLS, Geneva, Switzer-
land), which analysed the samples.
Statistical analysis
The Wilcoxon signed rank test was used to evaluate the per
cent changes from baseline in Kbone, BTM and BMD. Due
to the small sample size (n=10), the changes were plotted
as the median and interquartile range (IQR). The same test
was used to evaluate the changes in Kbone and BTM during
the 6-month period after stopping teriparatide therapy.
Statistical inferences were made based on a two-sided
significance level of 0.05.
Clinical laboratory and safety assessments
At screening, parathyroid hormone [PTH(1–84)], 25-
hydroxyvitamin D, 24-h urine calcium and clinical
chemistry were collected as previously described [24].
Measurements of serum calcium, alkaline phosphatase
(AP) and creatinine were repeated at each subsequent
visit. Adverse events were also assessed at each clinic
visit.
Fig. 1 ROI for the measurement of Kbone values for: a spine, pelvis,
upper extremities and lower extremities. For the upper extremities the
counts from the right and left arms were added together; b calvarium
and mandible
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Study population
The mean age of subjects was 68.3 years (± 8.0). On average,
subjects had severe osteoporosis with prevalent vertebral
fractures and a mean (± standard deviation) lumbar spine T-
scoreof−3.2±0.8(Table1). Clinical laboratory findings were
within the normal reference range at baseline. BTM were
within the reference ranges for postmenopausal women. All
ten subjects returned for the 3- and 18-month scans and nine
subjects returned for the 24-month visit.
Quantitative measurements of bone metabolism
using
99mTc-MDP
After 3 months of teriparatide therapy, the median per cent
increase from baseline in whole skeleton Kbone was 22.3%
(p=0.004), after 18 months the increase was 33.8% (p=
0.002), decreasing to 0.7% compared to baseline (p=0.57)
after 6 months off therapy (Fig. 2a). The decrease after
stopping therapy was statistically significant (p=0.004). In
subjects with a history of prior osteoporotic fracture, there
was negligible effect on global or regional skeletal uptake
of
99mTc-MDP to interfere with the quantitative measure-
ments [24]. The changes in Kbone values for the regional
sites are shown in Fig. 2b–f. After 3 months of teriparatide
treatment, the median increases from baseline in regional
Kbone values were statistically significant in each of the six
sites studied: calvarium 72.3%, mandible 65.9% (data not
shown), spine 17.3%, pelvis 20.3%, upper extremities
42.5% and lower extremities 21.0%. After 18 months of
teriparatide treatment, the changes from baseline were
statistically significant for five sites: calvarium 128.4%,
mandible 61.0% (data not shown), spine 33.8%, upper
extremities 95.5% and lower extremities 34.9%. The
change at the pelvis did not reach statistical significance
at 18 months. After 6 months off teriparatide treatment, the
median change from baseline in all regional Kbone values
declined towards baseline. The Kbone values at the spine
(16.9%) and the upper extremities (62.8%) remained
statistically significantly above baseline at 24 months. The
decrease in Kbone from 18 to 24 months was statistically
significant only at the calvarium and lower extremities.
Qualitative visual scoring of the
99mTc-MDP bone scan
images
Qualitative visual scoring of the bone scan images
compared with baseline at 3 and 18 months showed
increased skeletal uptake that varied within and between
subjects, with the 18-month changes more marked than
those at 3 months. Increased
99mTc-MDP uptake was
frequently noted in the calvarium and to a lesser extent in
the long bones of the lower extremities. In six subjects after
6 months off therapy, the uptake on the bone scan image
was visually indistinguishable from baseline. Of the other
three subjects, one subject showed a possible decrease in
uptake below baseline, and two subjects still had either a
possible or definite increase in uptake above baseline.
Figures 3, 4 and 5 show anterior and posterior views of
whole-body gamma camera bone scans and right lateral
skull views of three subjects who were chosen to illustrate
the range of visual changes. Tables 2, 3 and 4 show the
corresponding Kbone and BTM data. Figure 3 shows subject
1, with the most pronounced visual changes in skeletal
uptake of
99mTc-MDP in the whole skeleton that were
particularly prominent in the calvarium and long bones of
the legs. The values for whole skeleton Kbone, as well as
each regional site, and all BTM at 3 and 18 months were
substantially higher than the baseline values (Table 2) with
whole skeleton Kbone increasing by 76 and 60% at 3 and
18 months, respectively, while Kbone for the calvarium
increased by 152 and 188%, respectively. This subject
completed 18 months of teriparatide therapy, but was
subsequently lost to follow-up.
Figure 4 shows subject 2, with a definite increase in
skeletal uptake of
99mTc-MDP in the calvarium and
possibly subtler visual changes in the rest of the skeleton
compared to baseline at both 3 and 18 months. The changes
observed in the calvarium on the whole-body bone scans
are also supported by those seen in the lateral skull views.
Table 1 Baseline characteristics of the study population (n=10)
Characteristic Mean ± SD Reference range
a
Age (years) 68.3±8.0 –
Years postmenopausal 21.4±7.4 –
Body mass index (kg/m
2) 24.3±5.7 –
Lumbar spine T-score −3.2±0.8 –
Femoral neck T-score −2.5±0.8 –
BSAP (μg/l) 12.5±3.6 3.8–22.6
PINP (μg/l) 38.9±13.1 19.0–84.0
uNTx/Cr (nmol BCE/mmol Cr) 29.0±19.0 0–130
Serum creatinine (μmol/l) 72.8±6.7 31–101
Serum calcium (mmol/l) 2.5±0.1 2.1–2.6
Intact PTH(1–84) (pmol/l) 3.1 ±1.3 0.6–4.2
Serum AP (U/l) 69.0±15.0 35–123
BSAP bone-specific alkaline phosphatase, PINP N-terminal propep-
tide of collagen type I, uNTx/Cr urinary N-telopeptide normalized to
creatinine, BCE bone collagen equivalent
aReference ranges were provided by Covance Laboratories (Geneva,
Switzerland), which analysed the samples. Ranges for BSAP, uNTx/
Cr and AP are for postmenopausal women; all others are for adult
females
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scans and the lateral skull images returned to that observed
at baseline. The percentage change from baseline for whole
skeleton Kbone at 3 and 18 months for this subject was 23
and 33%, respectively (Table 3), which is similar to the
median per cent change observed for the study group. The
percentage change from baseline in Kbone for the calvarium
at 3 and 18 months was 116 and 161%, respectively,
diminishing to below the baseline value at 24 months.
Similarly, the Kbone value for whole skeleton returned to
below the baseline value at 24 months.
Figure 5 shows subject 3, with a possible increase in
skeletal uptake in the calvarium at 3 months and a definite
increase in skeletal uptake in this site at 18 months
compared to the baseline image, with the lateral skull
views supporting this interpretation. No clear visual
changes are observed in the rest of the skeleton at 3 and
18 months. At 24 months, the visual appearance of the
calvarium returned to that observed at the baseline visit.
The percentage change from baseline for whole skeleton
Kbone at 3 and 18 months for this subject was 20 and 30%,
respectively (Table 4), which is similar to the median per
cent change observed for the study group. The percentage
change in Kbone for the calvarium between baseline, 3, 18
and 24 months was 37, 104 and 21%, respectively.
BMD measurements and biochemical markers of bone
turnover
As reported previously, at 18 months the median percentage
change from baseline in BMD at the lumbar spine and total
hip was 8.7% (p=0.01) and 0.9% (p=0.30), respectively
[24]. At 3, 12 and 18 months, subjects had statistically
significant increases in concentrations of serum BSAP,
PINP and urinary NTX/creatinine ratio, and after 6 months
off therapy, all markers declined towards baseline (Fig. 6).
The decrease in BTM from 18 to 24 months, representing
6 months off therapy, was statistically significant for BSAP
(p=0.008) and PINP (p=0.004) but not for NTX (p=0.91).
Concentrations of serum AP were within the reference
range at baseline (Table 1), modestly elevated by 16.2% at
12 months (p=0.037) and returned to baseline at 24 months
(Fig. 6d).
BSAP and PINP were statistically significantly
correlated with whole skeleton Kbone values at 3 and
18 months (Spearman rank correlation coefficients 0.60
Fig. 2 Per cent changes from baseline of the Kbone values for the
whole skeleton and five of the six skeletal regional sites studied after 3
and 18 months of teriparatide, followed by 6 months off therapy. Data
are shown for all ten individual subjects (red lines) and the median
(black line). Error bars show the IQR. Data for the mandible are not
shown. a Whole skeleton Kbone, b calvarium Kbone, c spine Kbone, d
pelvis Kbone, e upper extremities Kbone, f lower extremities Kbone.
Kbone
99mTc-MDP skeletal plasma clearance, IQR interquartile range
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report [24].
Adverse events
Teriparatide was well tolerated in the study group, with
adverse events similar to those seen in larger clinical trials.
Serious adverse events in subjects on therapy were few and
reported previously [24]. During the 6 months off therapy,
no serious adverse events were reported. Subject 1 reported
randomly occurring mild joint/bone pain in the left leg after
taking teriparatide for 2 months. This continued for
8 months while the subject was receiving teriparatide, but
the severity did not increase or affect any other regions of
the skeleton during this period. After resolution of the pain,
the subject continued to receive teriparatide for a further
9 months without complaint.
Discussion
This is the first study to report the visual and quantitative
changes measured by radionuclide bone scan in subjects
undergoing 18 months of treatment with teriparatide
followed by 6 months off therapy. Although quantitative
changes at 3 and 18 months were previously described [24],
the present analysis examined the variety of visual changes
and compared these results to quantitative measures of
Kbone and BTM. Furthermore, this report describes the
effects of therapy withdrawal on qualitative and quantita-
tive measures of skeletal metabolism.
The study showed that quantitative measurements of
skeletal plasma clearance were a more robust indicator of
the effects of treatment than visual changes on the bone
scan images. After 3 and 18 months of teriparatide
treatment, measurements of whole skeleton and regional
Kbone were significantly increased compared with baseline,
with the value nearly doubling in subject 1. Greater
increases in Kbone were seen after 18 months of teriparatide
treatment compared with 3 months for the whole skeleton
and every regional site except the pelvis. The largest
changes in Kbone were observed in the calvarium, which
was also the site that showed the most pronounced visual
changes. Six months after stopping teriparatide, whole
skeleton and regional Kbone values returned toward baseline
values, although the calvarium and lower extremities
Fig. 3
99mTc-MDP anterior and posterior whole-body bone scans and right lateral skull views at baseline, 3 and 18 months for subject 1
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sites there was a statistically significant decrease between
18 and 24 months.
One subject (number 1) showed particularly pronounced
visual increases in
99mTc-MDP uptake throughout the
skeleton (Fig. 3). Of the other nine subjects, after 18 months
of teriparatide treatment, seven showed a definite increase
in uptake, one had possible increased uptake and one
showed no increase at any site. The changes were most
evident in the calvarium and, in some subjects, the long
bones of the lower extremities, with the change in contrast
between these areas and the rest of the skeleton providing
the clearest visual evidence of the metabolic response to
teriparatide treatment. Thus, the visual changes in bone
scan images during treatment with teriparatide appeared to
be variable and ranged from marked global increases in
uptake, to increases in the calvarium and lower extremities,
to increases in the calvarium alone, to no discernable
change (Figs. 3, 4 and 5). As expected after 6 months off
teriparatide therapy, the appearance of the bone scan images
was visually indistinguishable from baseline in most
subjects, which suggests that the metabolic changes in the
skeleton are the result of the anabolic mechanism of action
of teriparatide, and not due to other skeletal diseases.
In the literature, a case study has reported the possible
development of Paget’s disease of bone in the humerus and
Fig. 5
99mTc-MDP anterior and posterior whole-body bone scans and
right lateral skull views at baseline, 3, 18 and 24 months for subject 3
Fig. 4
99mTc-MDP anterior and posterior whole-body bone scans and
right lateral skull views at baseline, 3, 18 and 24 months for subject 2
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addition, when some patients taking teriparatide underwent
a bone scan to evaluate another medical condition, their
whole-body bone scans showed increased uptake of tracer
in the calvarium, which mimicked the appearance of
Paget’s disease of bone. In these reports, skeletal uptake
was diminished but persisted for 3 months after therapy
discontinuation. Since changes in
99mTc-MDP skeletal
uptake lag behind changes in bone formation, the final
bone scan in this study was obtained 6 months after
stopping teriparatide, so that it was possible to detect a
significant decrease in skeletal plasma clearance and study
the attenuation of the teriparatide-induced anabolic activity.
The pattern of tracer uptake observed with both visual and
quantitative assessments returned towards baseline 6 months
after stopping teriparatide therapy. This suggests that the
changes observed in these subjects during treatment are the
result of metabolic activity of the drug rather than a process
of bone pathology. Given the reported metabolic changes
induced by teriparatide treatment [12, 13] and the findings
described here, it is not surprising that similar visual
changes described previously have been attributed to bone
disease in individual cases. Although these findings provide
reference data for physicians when evaluating bone scan
changes in patients taking teriparatide, the presence of
underlying pathologies should be carefully considered in
conjunction with patient history and medical status.
The changes in spine and hip BMD and BTM reported
here are typical of those previously observed with teripara-
tide treatment [10–13]. Bone markers showed the greatest
increase between baseline and 3 months, generally peaked
at 12 months, and were unchanged or decreased at
18 months (Fig. 6). After 6 months off therapy, PINP and
NTX were still significantly increased, although they had
returned towards baseline values. Similar behaviour was
seen with BSAP and AP.
Table 2 Absolute values at
baseline, 3 and 18 months for
Kbone and bone turnover
markers in subject 1
Kbone
99mTc-MDP skeletal plas-
ma clearance, BSAP bone-
specific alkaline phosphatase,
PINP N-terminal propeptide of
collagen type I, uNTX/Cr uri-
nary N-telopeptide normalized
to creatinine, BCE bone colla-
gen equivalent
Parameter Baseline 3 months 18 months
Kbone (ml/min)
Whole skeleton 42.5 74.6 67.8
Calvarium 3.2 8.1 9.3
Mandible 0.2 0.4 0.6
Spine 5.7 8.0 9.0
Pelvis 5.8 10.1 10.0
Upper extremities 3.7 7.6 9.8
Lower extremities 8.3 24.2 20.4
Bone turnover markers
BSAP (μg/l) 7.5 15.5 14.4
PINP (μg/l) 38 216 190
uNTx/Cr (nmol BCE/nmol Cr) 20 169 202
AP (U/l) 47 71 71
Table 3 Absolute values at
baseline, 3, 18 and 24 months
for Kbone and bone turnover
markers in subject 2
Kbone
99mTc-MDP skeletal plas-
ma clearance, BSAP bone-
specific alkaline phosphatase,
PINP N-terminal propeptide of
collagen type I, uNTX/Cr uri-
nary N-telopeptide normalized
to creatinine, BCE bone colla-
gen equivalent
Parameter Baseline 3 months 18 months 24 months
Kbone (ml/min)
Whole skeleton 37.2 45.9 49.5 33.2
Calvarium 2.9 6.3 7.7 2.7
Mandible 0.1 0.2 0.2 0.2
Spine 6.7 9.0 9.2 7.8
Pelvis 6.8 7.6 6.4 5.3
Upper extremities 5.2 8.6 10.7 6.2
Lower extremities 9.7 8.4 9.2 8.1
Bone turnover markers
BSAP (μg/l) 19.2 15.5 18.0 14.3
PINP (μg/l) 57 136 149 48
uNTx/Cr (nmol BCE/nmol Cr) 61 77 41 65
AP (U/l) 81 72 73 66
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number of subjects. For this reason, it is unclear how
frequently a bone scan showing the pronounced visual
changes seen in Fig. 3 may occur as a result of teriparatide
treatment, or whether a response in terms of BTMs can
occur without a corresponding visual change in the bone
scan. The subjects in this study were all Caucasian
postmenopausal women, so information regarding the
changes observed on bone scans in other populations
treated with teriparatide is not available.
Nevertheless, this study has several strengths. Radionu-
clide bone scan images provide a unique way of visualizing
and comparing the metabolic changes in bone in response
to teriparatide therapy in different regions of the skeleton
compared with BTM that show only the average integrated
response. Quantitative measurements of skeletal plasma
Fig. 6 Per cent change from
baseline of BTMs after 3, 12
and 18 months of teriparatide
followed by 6 months off thera-
py. Data are shown for all ten
individual subjects (red lines)
and the median (black line).
Error bars show the IQR. a
BSAP, b PINP, c uNTX/Cr, d
Alk Phos. Alk Phos alkaline
phosphatase, BSAP serum bone-
specific alkaline phosphatase,
BTM bone turnover markers, IQR
interquartile range, uNTX/Cr uri-
nary excretion of N-terminal
telopeptide normalized to creati-
nine, PINP serum procollagen
type I N-terminal propeptide
Table 4 Absolute values at
baseline, 3, 18 and 24 months
for Kbone and bone turnover
markers in subject 3
Kbone
99mTc-MDP skeletal plas-
ma clearance, BSAP bone-
specific alkaline phosphatase,
PINP N-terminal propeptide of
collagen type I, uNTX/Cr uri-
nary N-telopeptide normalized
to creatinine, BCE bone colla-
gen equivalent
Parameter Baseline 3 months 18 months 24 months
Kbone (ml/min)
Whole skeleton 32.7 39.3 42.5 34.2
Calvarium 2.8 3.9 5.8 3.4
Mandible 0.2 0.2 0.2 0.2
Spine 6.7 7.2 8.6 7.7
Pelvis 6.2 6.5 6.7 6.8
Upper extremities 3.5 6.7 6.5 7.3
Lower extremities 6.5 8.1 9.4 7.5
Bone turnover markers
BSAP (μg/l) 9.2 10.7 13.2 8.7
PINP (μg/l) 32 56 99 46
uNTx/Cr (nmol BCE/nmol Cr) 17 36 39 47
AP (U/l) 66 65 69 63
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treatment than visual assessments alone and were able to
confirmtheregionaldifferencesobservedatsitesofprominent
visual changes such as the calvarium. This study provides
additional data suggesting that the calvarium is particularly
sensitive to the metabolic action of teriparatide, although
further study is required to determine the exact nature of this
response. Additionally, the concurrent assessment of radionu-
clide bone scans, BTM and BMD allowed for quantitative
comparisons between the visual images and Kbone measure-
ments with surrogate markers that show well-characterized
responses to teriparatide treatment.
Conclusion
We have reported the visual changes in the radionuclide
bone scan seen during teriparatide treatment and its
subsequent withdrawal. Increased skeletal uptake of
99mTc-MDP was observed in postmenopausal women with
osteoporosis treated with teriparatide, and the visual
changes were confirmed by quantitative measurements of
99mTc-MDP skeletal plasma clearance and BTM. The
changes were most frequently seen in the calvarium. After
6 months off teriparatide, the appearance of the bone scan
images returned toward baseline, and this was accompanied
by a decline in skeletal plasma clearance and BTM. The
results of this study may offer practical information to aid
the visual interpretation of bone scans in patients concur-
rently receiving teriparatide treatment.
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